Anatoli Pechenkin, Former Market Access Director, Bristol-Myers Squibb
Anatoli shared his experience & insight on the market access landscape in Russia. Russia’s pharma market sits outside of the top 10 largest pharma markets despite having the 9th largest population in the world.
The pharmaceutical market is predicted to grow at an annual compound growth rate of 13% & is set to be worth $36.6bn by 2021. The Russian government has laid out its future plans focusing on increasing localized production & fostering innovation.
We heard about these recent developments from Anatoli, who brings years of experience as a Director for Roche & Bristol-Myers Squibb on the current state of market access in Russia. He will also offered his opinion & insight on the latest MoH data released at the end of September 2021.